Sign In
Buy ARCT
$5.76
-0.160 (-2.70%)
At Close: Jul 31, 2026
Arcturus Therapeutics to Attend Upcoming Investor Conferences
08:30am, Thursday, 17'th Aug 2023
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company
New Strong Sell Stocks for August 10th
08:30am, Thursday, 10'th Aug 2023
ARCT, AVY and ASB have been added to the Zacks Rank #5 (Strong Sell) List on August 10, 2023.
Why Shares of Arcturus Therapeutics Dropped on Tuesday
02:39pm, Tuesday, 08'th Aug 2023
Arcturus Therapeutics has several collaboration agreements. The company is a clinical-stage biotech.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates
09:09pm, Monday, 07'th Aug 2023
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.98 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.82 per share a year ago.
3 Biotech Stocks to Buy Before the Breakout
05:14pm, Friday, 28'th Jul 2023
During this Q3 of 2023, there have been many changes to U.S. healthcare at different levels. At the state level, there were changes to gender-affirming care.
3 Biotech Stocks for Getting Rich in 2023
06:22am, Tuesday, 18'th Jul 2023
The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Me
Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?
06:02am, Monday, 17'th Jul 2023
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric
Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
01:40pm, Monday, 26'th Jun 2023
Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The comp
Arcturus Therapeutics (ARCT) Q1 Earnings and Revenues Miss Estimates
07:07pm, Tuesday, 09'th May 2023
Arcturus Therapeutics (ARCT) came out with quarterly earnings of $0.88 per share, missing the Zacks Consensus Estimate of $2.92 per share. This compares to loss of $1.94 per share a year ago.
What To Know About ‘Arcturus': New Covid Variant Causing Pink Eye
06:07pm, Thursday, 27'th Apr 2023
New Covid strain XBB.1.18, nicknamed arcturus, is quickly spreading across the U.S., but experts are warning that pink eye and high fever, two symptoms of the new variant, are particularly present amo
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
08:30am, Wednesday, 26'th Apr 2023
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023.
Unlocking Arcturus' Potential And De-Risking Through Partnerships
01:03pm, Tuesday, 11'th Apr 2023
Arcturus is executing well, utilizing strategic partnerships with CSL and Meiji to de-risk its financial position. The company has reinforced its management team by appointing a CMO and CDO, bringing
Why Arcturus Therapeutics Stock Is Soaring Today
11:45am, Wednesday, 29'th Mar 2023
Arcturus beat expectations with its Q4 results. The company also provided an encouraging update on its pipeline programs.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2022 Earnings Call Transcript
07:02pm, Tuesday, 28'th Mar 2023
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Neda Safarzadeh - IR Joseph Payne - President & CEO Andrew Sassine -
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
06:18pm, Tuesday, 28'th Mar 2023
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
